Comparison · NCT05064735-deaths
Semaglutide 2.4 mg vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Semaglutide 2.4 mg vs Placebo: deaths from any cause. Trial comparisons, record NCT05064735-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05064735-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0141 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0277 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0277 | 0.0141 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Semaglutide 2.4 mg | Participants initiated at a once-weekly dose of 0.24 mg semaglutide s.c. as a adjunct to a reduced calorie diet and increased physical activity and followed a fixed-dose escalation regimen, with dose increase every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose was reached after 16 weeks. Participants continued 2.4 mg semaglutide s.c. once- weekly from week 16 to week 68 as a adjunct to a reduced calorie diet and increased physical activity. Participants were followed up for 7 weeks after end of treatment till week 75. | 0 | 269 | EG000 |
| Group 2 | Placebo | Participants received semaglutide matching placebo subcutaneously once weekly as a adjunct to a reduced calorie diet and increased physical activity from week 0 to week 68. Participants were followed up for 7 weeks after end of treatment till week 75. | 0 | 135 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From baseline (week 0) to end of trial (week 75)
Source ClinicalTrials.gov
Trial
- Title
- Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- NCT number
- NCT05064735
- Phases
- PHASE3
- Conditions
- Obesity
- Interventions
- semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
- Lead sponsor
- Novo Nordisk A/S
- Results first posted
- 2024-08-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05064735?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05064735-deaths